OBJECTIVES: The feasibility of providing prolonged and controlled release of the experimental non-nucleoside reverse transcriptase inhibitor TMC120 from a silicone vaginal ring in quantities sufficient to maintain a vaginal concentration offering protection against heterosexual HIV transmission was investigated. METHODS: Core-type, silicone elastomer vaginal rings containing TMC120 were manufactured, and in vitro release studies performed under sink conditions. The experimental release data, as determined by HPLC, were correlated with estimates of vaginal TMC120 concentrations required to inhibit HIV replication. RESULTS: Continuous, zero-order release of TMC120 from core-type vaginal rings was observed in vitro over a 71 day period, equivalent to 136 microg/day. The release rate is predicted to maintain vaginal concentrations of the antiretroviral in the range of several orders of magnitude in excess of reported HIV inhibitory concentration values. CONCLUSIONS: Continuous and prolonged zero-order release of TMC120 from a silicone vaginal ring device at quantities predicted to prevent HIV infection was observed.
OBJECTIVES: The feasibility of providing prolonged and controlled release of the experimental non-nucleoside reverse transcriptase inhibitor TMC120 from a silicone vaginal ring in quantities sufficient to maintain a vaginal concentration offering protection against heterosexual HIV transmission was investigated. METHODS: Core-type, silicone elastomer vaginal rings containing TMC120 were manufactured, and in vitro release studies performed under sink conditions. The experimental release data, as determined by HPLC, were correlated with estimates of vaginal TMC120 concentrations required to inhibit HIV replication. RESULTS: Continuous, zero-order release of TMC120 from core-type vaginal rings was observed in vitro over a 71 day period, equivalent to 136 microg/day. The release rate is predicted to maintain vaginal concentrations of the antiretroviral in the range of several orders of magnitude in excess of reported HIV inhibitory concentration values. CONCLUSIONS: Continuous and prolonged zero-order release of TMC120 from a silicone vaginal ring device at quantities predicted to prevent HIV infection was observed.
Authors: Ronald S Veazey; Thomas A Ketas; Per Johan Klasse; Donna K Davison; Morgan Singletary; Linda C Green; Michael L Greenberg; John P Moore Journal: Proc Natl Acad Sci U S A Date: 2008-07-22 Impact factor: 11.205
Authors: Hairui Li; Bin Jiang; Jun Yan; Zhonghua Yang; Yanni Chen; Weiping Zhang; Alex C Choy; Chi-Ying M Lee; Lifeng Kang Journal: Drug Deliv Transl Res Date: 2011-12 Impact factor: 4.617
Authors: Christopher McConville; James M Smith; Clare F McCoy; Priya Srinivasan; James Mitchell; Angela Holder; Ron A Otten; Salvatore Butera; Gustavo F Doncel; David R Friend; R Karl Malcolm Journal: Drug Deliv Transl Res Date: 2015-02 Impact factor: 4.617
Authors: Andrew Loxley; Mark Mitchnick; Onajite Okoh; Jason McConnell; Laurie Goldman; Christopher Morgan; Meredith Clark; David R Friend Journal: Drug Deliv Transl Res Date: 2011-06 Impact factor: 4.617
Authors: Claire J Forbes; Clare F McCoy; Diarmaid J Murphy; A David Woolfson; John P Moore; Abbey Evans; Robin J Shattock; R Karl Malcolm Journal: J Pharm Sci Date: 2014-03-01 Impact factor: 3.534